Related Experiment Video

Updated: Apr 18, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Adiponectin serum level in chronic hepatitis C infection and therapeutic profile

Valentina Peta1, Carlo Torti1, Natasa Milic1

  • 1Valentina Peta, Alfredo Focà, Ludovico Abenavoli, Department of Health Sciences, University Magna Græcia, Campus Germaneto, 88100 Catanzaro, Italy.

World Journal of Hepatology
|January 28, 2015
PubMed

Insights

Hepatitis C virus (HCV) infection is linked to liver steatosis, particularly in genotype 3. Lower levels of adiponectin, a hormone regulating metabolism, correlate with increased liver fat in HCV patients.

Area of Science:

  • Hepatology
  • Virology
  • Metabolic Research

Background:

  • Hepatic steatosis (fatty liver) is a common complication in patients with chronic hepatitis C virus (HCV) infection.
  • HCV impacts lipid metabolism; genotype 3 causes viral steatosis via HCV core protein, while other genotypes (e.g., genotype 1) lead to metabolic steatosis due to host metabolic alterations.
  • Adipocytokines, such as adiponectin, play a role in fatty liver disease pathogenesis, with decreased levels associated with steatosis.

Purpose of the Study:

  • To explore the association between adiponectin levels and hepatic steatosis in patients with HCV infection.
  • To elucidate the potential mechanisms by which adiponectin influences HCV-related liver steatosis.

Main Methods:

  • This study reviews existing literature and clinical observations regarding HCV infection, hepatic steatosis, and adiponectin.
  • Analysis of correlations between steatosis severity and plasma adiponectin levels in HCV-infected individuals.

Main Results:

  • A significant negative correlation exists between plasma adiponectin levels and the presence/severity of hepatic steatosis in HCV patients.
  • HCV genotype influences the mechanism of steatosis development, with genotype 3 linked to direct viral effects and other genotypes to metabolic dysregulation.

Conclusions:

  • Low adiponectin levels are strongly associated with hepatic steatosis in HCV infection.
  • Adiponectin may protect hepatocytes from fat accumulation by enhancing fatty acid oxidation and reducing fat synthesis, thus mitigating HCV-induced steatosis.

Keywords:
AdiponectinHepatitis C virusHepatitis C virus core proteinInsulin resistanceMetabolism

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.2K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
266
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
365
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
340